First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer

Cited by (1,001)

Items 101–200 of 1,001

1. Personalized Medicine: Recent Progress in Cancer Therapy
   Valentina Gambardella, Noelia Tarazona, Juan Miguel Cejalvo, Pasquale Lombardi, Marisol Huerta, Susana Roselló, Tania Fleitas, Desamparados Roda, Andrès M.R. Cervantes · 2020 · Cancers
2. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)
   Brandon Golding, Anita K. Luu, Robert A. Jones, Alicia Viloria‐Petit · 2018 · Molecular Cancer
3. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study
   Caicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana, Jianying Zhou, Yiping Zhang, Jianxing He, Jin‐Ji Yang, Ying Cheng, Se‐Hoon Lee, Lilian Bu et al. · 2019 · The Lancet Respiratory Medicine
4. Receptor Tyrosine Kinase-Targeted Cancer Therapy
   Yamaoka, Toshimitsu, Kusumoto, Sojiro, Ando, Koichi, Ohba, Motoi, Ohmori, Tohru · 2018 · International Journal of Molecular Sciences
5. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer
   Gorjan Hrustanovic, Victor R. Olivas, Evangelos Pazarentzos, Asmin Tulpule, Saurabh Asthana, Collin Michael Blakely, Ross A. Okimoto, Luping Lin, Dana S. Neel, Amit J. Sabnis et al. · 2015 · Nature Medicine
6. Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer
   Justin F. Gainor, Diane Tseng, Satoshi Yoda, Ibiayi Dagogo‐Jack, Luc Friboulet, Jessica J. Lin, Harper Hubbeling, Leila Dardaei, Anna F. Farago, Katherine R. Schultz et al. · 2017 · JCO Precision Oncology
7. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non–Small-Cell Lung Cancer: Results From PROFILE 1014
   Benjamin Solomon, Federico Cappuzzo, Enriqueta Felip, Fiona Helen Blackhall, Daniel Botelho Costa, Dong‐Wan Kim, Kazuhiko Nakagawa, Yi-Long Lung Cancer Wu, Tarek M. Mekhail, Jolanda Paolini et al. · 2016 · Journal of Clinical Oncology
8. Recent Advances in Targeting ROS1 in Lung Cancer
   Jessica J. Lin, Alice Tsang Shaw · 2017 · Journal of Thoracic Oncology
9. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
   Baohui Han, Kai Li, Yizhuo Zhao, Baolan Li, Ying Cheng, Jianying Zhou, You Lü, Yuankai Shi, Zhehai Wang, Liyan Jiang et al. · 2018 · British Journal of Cancer
10. Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
    Ryohei Katayama, Christine Marie Lovly, Alice Tsang Shaw · 2015 · Clinical Cancer Research
11. Lung Cancer Biomarkers
    Pamela Andrea Villalobos, Ignacio Ivan Wistuba · 2016 · Hematology/Oncology Clinics of North America
12. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer
    Leora Horn, Ziping Wang, Gang Wu, Elena V Poddubskaya, Tony S.K. Mok, Martin Reck, Heather A. Wakelee, Alberto Chiappori, Ki Hyeong Lee, Valeriy Vladimirovich Breder et al. · 2021 · JAMA Oncology
13. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer
    C. Lim, Ming‐Sound Tsao, Lisa W. Le, Frances A. Shepherd, Ronald D. Feld, Ronald L. Burkes, Geoffrey Liu, Suzanne Kamel‐Reid, D. Hwang, Jeffrey Tanguay et al. · 2015 · Annals of Oncology
14. Therapeutic management options for stage III non-small cell lung cancer
    Stephanie M Yoon, Talha Shaikh, Mark A. Hallman · 2017 · World Journal of Clinical Oncology
15. Progress on pivotal role and application of exosome in lung cancer carcinogenesis, diagnosis, therapy and prognosis
    Mingyue Li, Lizhong Liu, Ming Dong · 2021 · Molecular Cancer
16. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
    Benjamin Solomon, Todd Michael Bauer, Tony S.K. Mok, Geoffrey Liu, Julien Mazières, Filippo de Marinis, Yasushi Goto, Dong‐Wan Kim, Yi-Long Lung Cancer Wu, Jacek Jassem et al. · 2022 · The Lancet Respiratory Medicine
17. Resisting Resistance: Targeted Therapies in Lung Cancer
    Jessica J. Lin, Alice Tsang Shaw · 2016 · Trends in cancer
18. Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
    Cheri A. Pasch, Peter F. Favreau, Alexander E. Yueh, Christopher P. Babiarz, Amani A. Gillette, Joe T. Sharick, Mohammad Rezaul Karim, Kwangok P. Nickel, Alyssa K. DeZeeuw, Carley M. Sprackling et al. · 2019 · Clinical Cancer Research
19. Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy
    Olga Rodak, Manuel David Peris‐Díaz, Mateusz Olbromski, Marzenna Podhorska‐Okołów, Piotr Dzięgiel · 2021 · Cancers
20. Clinical development of targeted and immune based anti-cancer therapies
    Nicole A. Seebacher, Alexandra E. Stacy, Georgia Porter, Angelica M. Merlot · 2019 · Journal of Experimental & Clinical Cancer Research
21. Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)
    Spigel, David R., Reynolds, Craig, Waterhouse, David, Garon, Edward B., Chandler, Jason, Babu, Sunil, Thurmes, Paul, Spira, Alexander, Jotte, Robert, Zhu, Jin et al. · 2018 · Journal of Thoracic Oncology
22. Detection of NRG1 Gene Fusions in Solid Tumors
    Sushma Jonna, Rebecca A. Feldman, Jeffrey J. Swensen, Zoran Gatalica, Wolfgang Michael Korn, Hossein Borghaei, Patrick C. Ma, Jorge J. Nieva, Alexander I. Spira, Ari M. Vanderwalde et al. · 2019 · Clinical Cancer Research
23. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
    Zhang, Chengwei, Han, Xiao-Ran, Yang, Xiaobao, Jiang, Biao, Liu, Jing, Xiong, Yue, Jin, Jian · 2018 · European Journal of Medicinal Chemistry
24. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications
    Helen Gharwan, Hunter Groninger · 2015 · Nature Reviews Clinical Oncology
25. EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients
    Sarah R. Sabir, Sharon Yeoh, George Jackson, Richard W. Bayliss · 2017 · Cancers
26. HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence
    Fu, Jianjiang, Su, Xiaorui, Li, Zhihua, Deng, Ling, Liu, Xiawei, Feng, Xuancheng, Peng, Juan · 2021 · Oncogene
27. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
    Riccardo Antonio Lencioni, Robert Montal, Ferràn Torres, Joong‐Won Park, Thomas Decaens, Jean‐Luc Raoul, Masatoshi Kudo, Charissa Chang, José Ríos, Valérie Boige et al. · 2017 · Journal of Hepatology
28. Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer
    Roberto Ferrara, Nathalie Auger, Édouard Auclin, Benjamin Besse · 2017 · Journal of Thoracic Oncology
29. Insights into the success and failure of systemic therapy for hepatocellular carcinoma
    Jordi Bruix, Leonardo Gomes da Fonseca, María Reig · 2019 · Nature Reviews Gastroenterology & Hepatology
30. Testing for ROS1 in non-small cell lung cancer: a review with recommendations
    Lukas Bubendorf, Reinhard Büttner, Fouad Al‐Dayel, Manfred Dietel, Göran Elmberger, Keith M. Kerr, Fernando López‐Ríos, Antonio Marchetti, Büğe Öz, Patrick Pauwels et al. · 2016 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
31. Differential protein stability and clinical responses ofEML4-ALK fusion variants to various ALK inhibitors in advancedALK-rearranged non-small cell lung cancer
    Chang Gok Woo, Seyoung Seo, Sang Wan Kim, Seongsoo Jang, K.S. Park, Ji‐Young Song, Bora Lee, Mark W. Richards, Richard W. Bayliss, D.H. Lee et al. · 2016 · Annals of Oncology
32. Drug resistance to targeted therapeutic strategies in non-small cell lung cancer
    Wenjuan Liu, Yue Du, Ru M. Wen, Ming Yang, Jian Xu · 2019 · Pharmacology & Therapeutics
33. Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy
    Renumathy Dhanasekaran, Jean‐Charles Nault, Lewis Rowland Roberts, Jessica Zucman‐Rossi · 2018 · Gastroenterology
34. CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer
    Man Zhang, Wei Zhong Yang, Peng Wang, Yu Deng, Yuting Dong, Fangfang Liu, Rui Huang, Peng Zhang, Yaqi Duan, Xindong Liu et al. · 2020 · Nature Communications
35. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma
    Mrinal M. Gounder, Narasimhan P. Agaram, Sally E. Trabucco, Victoria L. Robinson, Richard Ferraro, Sherri Z. Millis, Anita Krishnan, Jessica Lee, Steven Attia, Wassim M. Abida et al. · 2022 · Nature Communications
36. Precision Management of Advanced Non–Small Cell Lung Cancer
    Ching‐Yao Yang, James Chih‐Hsin Yang, Pan‐Chyr Yang · 2020 · Annual Review of Medicine
37. MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
    Ibiayi Dagogo‐Jack, Satoshi Yoda, Jochen K. Lennerz, Adam Langenbucher, Jessica J. Lin, Marguerite M. Rooney, Kylie Prutisto-Chang, Audris Oh, Nathaniel A. Adams, Beow Yong Yeap et al. · 2020 · Clinical Cancer Research
38. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non–Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib
    Patil, Tejas, Smith, Derek E., Bunn, Paul A., Aisner, Dara L., Le, Anh T., Hancock, Mark, Purcell, William T., Bowles, Daniel W., Camidge, D. Ross, Doebele, Robert C. · 2018 · Journal of Thoracic Oncology
39. Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions
    Ayal Aaron Aizer, Nayan Lamba, Manmeet Singh Ahluwalia, Kenneth Aldape, Adrienne Ann Boire, Priscilla Kaliopi Brastianos, Paul D. Brown, D. Ross Camidge, Veronica Chiang, Michael A. Davies et al. · 2022 · Neuro-Oncology
40. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
    Qing Wu, Wei Qian, Xiaoli Sun, Shaojie Jiang · 2022 · Journal of Hematology & Oncology
41. Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography
    Daniel S.W. Tan, Tony S.K. Mok, Timothy Richard Rebbeck · 2015 · Journal of Clinical Oncology
42. Lung cancer in never smokers—the East Asian experience
    Fei Zhou, Caicun Zhou · 2018 · Translational Lung Cancer Research
43. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer
    R. Jonas A. Nilsson, Niki Karachaliou, Jordi Berenguer, Ana A. Giménez-Capitán, Pepijn Schellen, Cristina Teixidó, Jihane M. Tannous, Justine Leonie Kuiper, Esther E.E. Drees, Magda Grabowska et al. · 2015 · Oncotarget
44. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
    Leila Dardaei, Hui Qin Wang, Manrose Singh, Paul Fordjour, Katherine X Shaw, Satoshi Yoda, Gráinne Kerr, Kristine Yu, Jinsheng Liang, Yichen Cao et al. · 2018 · Nature Medicine
45. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
    Kron, A., Alidousty, C., Scheffler, M., Merkelbach-Bruse, S., Seidel, D., Riedel, R., Ihle, M.A., Michels, S., Nogova, L., Fassunke, J. et al. · 2018 · Annals of Oncology
46. KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
    Helen Adderley, Fiona Helen Blackhall, Colin R. Lindsay · 2019 · EBioMedicine
47. Targeted therapies for treatment of non‐small cell lung cancer—Recent advances and future perspectives
    Joan Minguet, Katherine Helen Smith, Peter Bramlage · 2015 · International Journal of Cancer
48. Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era
    Jordi Remón, Émilie Le Rhun, Benjamin Besse · 2016 · Cancer Treatment Reviews
49. ALK: a tyrosine kinase target for cancer therapy
    Vijaykumar R. Holla, Yasir Y. Elamin, Ann Marie Bailey, Amber M. Johnson, Beate C. Litzenburger, Yekaterina B. Khotskaya, Nora Sánchez, Jia Zeng, Md Abu Shufean, Kenna R Mills Shaw et al. · 2017 · Molecular Case Studies
50. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK -Positive Non–Small-Cell Lung Cancer
    Shirish M. Gadgeel, Alice Tsang Shaw, Ramaswamy Govindan, Leena Gandhi, Mark A. Socinski, D. Ross Camidge, Luigi De Petris, Dong‐Wan Kim, Alberto Chiappori, Denis Moro‐Sibilot et al. · 2016 · Journal of Clinical Oncology
51. Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
    Leora Horn, Jeffrey R. Infante, Karen L. Reckamp, George R. Blumenschein, Ticiana A.B. Leal, Saiama Naheed Waqar, Barbara Jennifer Gitlitz, Rachel E. Sanborn, Jennifer G. Whisenant, Liping Du et al. · 2018 · Clinical Cancer Research
52. Small molecule inhibitors targeting the cancers
    Guihong Liu, Tao Chen, Xin Zhang, Xuelei Ma, Shi H · 2022 · MedComm
53. ALK-positive lung cancer: a moving target
    Jaime Laurel Schneider, Jessica J. Lin, Alice Tsang Shaw · 2023 · Nature Cancer
54. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors
    Émmanuelle Vigarios, Joel Brian Epstein, Vincent Sibaud · 2017 · Supportive Care in Cancer
55. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
    Joshua Saul Davis, David Ferreira, Emma K. Paige, Craig A. Gedye, Michael Boyle · 2020 · Clinical Microbiology Reviews
56. Novel therapeutic targets on the horizon for lung cancer
    Wan-Ling Tan, Amit Jain, Angela Maria Takano, Evan William Newell, Narayanan Gopalakrishna Iyer, Wan‐Teck Lim, Eng-Huat Tan, Weiwei Zhai, Axel M. Hillmer, Wai Leong Tam et al. · 2016 · The Lancet Oncology
57. Current Landscape of Targeted Therapy in Lung Cancer
    Manasi K. Mayekar, Trever Grant Bivona · 2017 · Clinical Pharmacology & Therapeutics
58. ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data
    Filippo Gustavo Dall’Olio, Ilaria Maggio, Maria Massucci, Veronica Mollica, Benedetta Fragomeno, Andrea Ardizzoni · 2020 · Lung Cancer
59. KRAS ‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
    Chengming Liu, Sufei Zheng, Zhanyu Wang, Sihui Wang, Xin‐Feng Wang, Lu Yang, Haiyan Xu, Zheng Cao, Xiaoli Feng, Qi Xue et al. · 2022 · 癌症：英文版
60. Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer
    Yi-Long Lung Cancer Wu, Shun Lü, You Lü, Jianying Zhou, Yuankai Shi, Virote Sriuranpong, Jcm Ho, Choo Khoon Ong, Chun‐Ming Tsai, Chin‐Hee Chung et al. · 2018 · Journal of Thoracic Oncology
61. Management of brain metastases according to molecular subtypes
    Riccardo Soffietti, Manmeet Singh Ahluwalia, NU Lin, Roberta Rudà · 2020 · Nature Reviews Neurology
62. SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
    Margarita Majem, Óscar Juan, Amelia Insa, Noemı́ Reguart, José Manuel Trigo, Enric Carcereny, Rosario García‐Campelo, Yolanda García García, María Guirado, Mariano Provencio · 2018 · Clinical & Translational Oncology
63. Clinical Management of Adverse Events Associated with Lorlatinib
    Todd Michael Bauer, Enriqueta Felip, Benjamin Solomon, Holger C. Thurm, Gerson Peltz, Marc D. Chioda, Alice Tsang Shaw · 2019 · The Oncologist
64. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer
    Gideon Michael Blumenthal, Yuexuan Gong, Kenneth L. Kehl, Pallavi Shruti Mishra-Kalyani, Kirsten B. Goldberg, Sean Khozin, Paul Gustav Kluetz, Geoffrey R. Oxnard, Richard Pazdur · 2019 · Annals of Oncology
65. Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?
    Joseph A. Pinto, Carlos Santiago Vallejos, Luis Estuardo Raez, Luis A. Mas, Rossana Ruiz, Junior Smith Torres-Román, Zaida Morante, Jhajaira M. Araujo, Henry Gómez, Alfredo Aguilar et al. · 2018 · ESMO Open
66. Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease
    Crispin T. Hiley, John P. C. Le Quesne, George Santis, Rowena Sharpe, David González de Castro, Gary Middleton, Charles Swanton · 2016 · The Lancet
67. Crizotinib resistance: implications for therapeutic strategies
    Ibiayi Dagogo‐Jack, Alice Tsang Shaw · 2016 · Annals of Oncology
68. Renal Cell Tumors: Understanding Their Molecular Pathological Epidemiology and the 2016 WHO Classification
    Kentaro Inamura · 2017 · International Journal of Molecular Sciences
69. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis
    Kang Qin, Helei Hou, Liang Yu, Xiaochun Zhang · 2020 · BMC Cancer
70. Is cancer biology different in older patients?
    Yannick Van Herck, Annelies Feyaerts, Shabbir M.H. Alibhai, Demetris Papamichael, Lore Decoster, Yentl Lambrechts, Michael Pinchuk, Oliver Edgar Bechter, Jaime Omar Herrera-Caceres, Frédéric Bibeau et al. · 2021 · The Lancet Healthy Longevity
71. Review article: systemic treatment of hepatocellular carcinoma
    Matthias Pinter, Markus Peck‐Radosavljevic · 2018 · Alimentary Pharmacology & Therapeutics
72. Molecular biomarkers for lung adenocarcinoma
    Olivier Calvayrac, Anne Pradines, Elvire Pons Tostivint, Julien Mazières, Nicolas Marie Guibert · 2017 · European Respiratory Journal
73. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
    Itziar Otano, Alvaro Conrado Ucero, Jon Zugazagoitia, Luis G Paz-Ares · 2023 · Nature Reviews Clinical Oncology
74. Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy
    Hidekazu Hirano, Ken Kato · 2019 · Japanese Journal of Clinical Oncology
75. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches
    Meghan Shea, Daniel Botelho Costa, Deepa Rangachari · 2015 · Therapeutic Advances in Respiratory Disease
76. Second- and third-generation ALK inhibitors for non-small cell lung cancer
    Jingjing Wu, John Savooji, Delong Liu · 2016 · Journal of Hematology & Oncology
77. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
    M. Duruisseaux, Benjamin Besse, Jacques L. Cadranel, Maurice Pérol, B. Mennecier, Laurence Bigay-Game, R. Descourt, Éric Dansin, Clarisse Audigier-Valette, Lionel Moreau et al. · 2017 · Oncotarget
78. Update on Immunohistochemistry for the Diagnosis of Lung Cancer
    Kentaro Inamura · 2018 · Cancers
79. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients
    Laure Sorber, Karen Zwaenepoel, Vanessa Deschoolmeester, Paul E. Van Schil, Jan P. van Meerbeeck, Filip Lardon, Christian Diego Rolfo, Patrick Pauwels · 2016 · Lung Cancer
80. ALK in Neuroblastoma: Biological and Therapeutic Implications
    Ricky M. Trigg, Suzanne Dawn Turner · 2018 · Cancers
81. Emerging therapies for non-small cell lung cancer
    Chao Zhang, Natasha B. Leighl, Yi-Long Lung Cancer Wu, Wen‐Zhao Zhong · 2019 · Journal of Hematology & Oncology
82. EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3
    Jaemoon Koh, Ji-Young Jang, Bhumsuk Keam, Sehui Kim, Moon‐Young Kim, Heounjeong Go, Tae Min Kim, Dong‐Wan Kim, Chul Woo Kim, Yoon Kyung Jeon et al. · 2015 · OncoImmunology
83. Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
    Caroline Elizabeth McCoach, Collin Michael Blakely, Kimberly C. Banks, Benjamin Philip Levy, Ben Man-Fai Chue, Victoria M. Raymond, Anh Tuan Le, Christine E. Lee, Joseph Diaz, Saiama Naheed Waqar et al. · 2018 · Clinical Cancer Research
84. Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers
    Jiang, Tingting, Wang, Guan, Liu, Yao, Feng, Lu, Wang, Meng, Liu, Jie, Chen, Yi, Ouyang, Liang · 2021 · Acta Pharmaceutica Sinica B
85. Personalized therapy for lung cancer: striking a moving target
    Suchita Pakkala, Suresh S. Ramalingam · 2018 · JCI Insight
86. Reactive Oxygen Species‐Mediated Mechanisms of Action of Targeted Cancer Therapy
    Teppo, Hanna-Riikka, Soini, Ylermi, Karihtala, Peeter · 2017 · Oxidative Medicine and Cellular Longevity
87. Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non–Small Cell Lung Cancer
    Jose M. Pacheco, Dexiang Gao, Derek E. Smith, Thomas Purcell, Mark Jonathan Hancock, Paul A. Bunn, Tyler P. Robin, Arthur J. Liu, Sana D. Karam, Laurie E. Gaspar et al. · 2018 · Journal of Thoracic Oncology
88. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
    Hiroaki Akamatsu, Kiichiro Ninomiya, Hirotsugu Kenmotsu, Masahiro Morise, Haruko Daga, Yasushi Goto, Toshiyuki Kozuki, Satoru Miura, Takaaki Sasaki, Akihiro Tamiya et al. · 2019 · International Journal of Clinical Oncology
89. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial
    Rudolf Maria Huber, Karin Holmskov Hansen, Luis Paz-Ares Rodríguez, Howard West, Karen L. Reckamp, Natasha B. Leighl, Marcello Tiseo, Egbert Frederik Smit, Dong‐Wan Kim, Scott N. Gettinger et al. · 2019 · Journal of Thoracic Oncology
90. Molecular Tumor Boards: current practice and future needs
    Daphne Liselotte Van Der Velden, Carla M.L. van Herpen, Hanneke W.M. van Laarhoven, Egbert Frederik Smit, Harry J.M. Groen, Stefan M. Willems, Petra M. Nederlof, Marlies H.G. Langenberg, Edwin P. J. G. Cuppen, Stefan Sleijfer et al. · 2017 · Annals of Oncology
91. Role and targeting of anaplastic lymphoma kinase in cancer
    Carminia Maria Della Corte, Giuseppe Viscardi, Raimondo Di Liello, Morena Fasano, Erika Martinelli, Teresa Troiani, Fortunato Ciardiello, Floriana Morgillo · 2018 · Molecular Cancer
92. The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications
    Hongmei Zheng, Yuting Zhan, Sile Liu, Junmi Lu, Jiadi Luo, Juan Feng, Songqing Fan · 2018 · Journal of Experimental & Clinical Cancer Research
93. Oncogenic alterations in advanced NSCLC: a molecular super-highway
    Alex Friedlaender, Maurice Pérol, Giuseppe Luigi Banna, Kaushal Parikh, Alfredo Addeo · 2024 · Biomarker Research
94. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
    Ryohei Katayama, Takuya Sakashita, Noriko Yanagitani, Hironori Ninomiya, Atsushi Horiike, Luc Friboulet, Justin F. Gainor, Noriko Motoi, Akito Dobashi, Seiji Sakata et al. · 2015 · EBioMedicine
95. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials
    D. Ross Camidge, Dong‐Wan Kim, Marcello Tiseo, Corey Jay Langer, Myung‐Ju Ahn, Alice Tsang Shaw, Rudolf Maria Huber, Maximilian Johannes Hochmair, Ki Hyeong Lee, Lyudmila A. Bazhenova et al. · 2018 · Journal of Clinical Oncology
96. Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune
    Zhansheng Jiang, Yanfang Yang, Yinli Yang, Yu Zhang, Zhensong Yue, Zhanyu Pan, Xiubao Ren · 2017 · Biomedicine & Pharmacotherapy
97. Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression
    Daniele Tavernari, Elena Battistello, Elie Dheilly, Aaron S. Petruzzella, Marco Mina, Jessica Sordet‐Dessimoz, Solange Peters, Thorsten Krueger, David Gfeller, Nicolò Riggi et al. · 2021 · Cancer Discovery
98. Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
    Edouard Dantoing, Nicolas Piton, Mathieu Salaün, Luc Thiberville, Florian Guisier · 2021 · International Journal of Molecular Sciences
99. Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions
    Young Kwang Chae, Michael S. Oh · 2018 · Journal of Thoracic Oncology
100. c-Met as a Target for Personalized Therapy
     Ingrid Garajová, Elisa Giovannetti, Guido Biasco, Godefridus J. Peters · 2015 · Translational Oncogenomics